|
1
|
Welzel TM, McGlynn KA, Hsing AW, O'Brien
TR and Pfeiffer RM: Impact of classification of hilar
cholangiocar-cinomas (Klatskin tumors) on the incidence of intra-
and extrahepatic cholangiocarcinoma in the United States. J Natl
Cancer Inst. 98:873–875. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Khan SA, Davidson BR, Goldin RD, Heaton N,
Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD,
Thillainayagam AV, et al British Society of Gastroenterology:
Guidelines for the diagnosis and treatment of cholangiocarcinoma:
An update. Gut. 61:1657–1669. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Everhart JE and Ruhl CE: Burden of
digestive diseases in the United States Part III: Liver, biliary
tract, and pancreas. Gastroenterology. 136:1134–1144. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tyson GL and El-Serag HB: Risk factors for
cholangiocarcinoma. Hepatology. 54:173–184. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Razumilava N and Gores GJ:
Cholangiocarcinoma. Lancet. 383:2168–2179. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Matsumoto R, Matsumoto H, Seki M, Hata M,
Asano Y, Kanegasaki S, Stevens RL and Hirashima M: Human ecalectin,
a variant of human galectin-9, is a novel eosinophil
chemoattractant produced by T lymphocytes. J Biol Chem.
273:16976–16984. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Matsushita N, Nishi N, Seki M, Matsumoto
R, Kuwabara I, Liu FT, Hata Y, Nakamura T and Hirashima M:
Requirement of divalent galactoside-binding activity of
ecalectin/galectin-9 for eosinophil chemoattraction. J Biol Chem.
275:8355–8360. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Matsumoto R, Hirashima M, Kita H and
Gleich GJ: Biological activities of ecalectin: A novel
eosinophil-activating factor. J Immunol. 168:1961–1967. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Saita N, Goto E, Yamamoto T, Cho I,
Tsumori K, Kohrogi H, Maruo K, Ono T, Takeya M, Kashio Y, et al:
Association of galectin-9 with eosinophil apoptosis. Int Arch
Allergy Immunol. 128:42–50. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Asakura H, Kashio Y, Nakamura K, Seki M,
Dai S, Shirato Y, Abedin MJ, Yoshida N, Nishi N, Imaizumi T, et al:
Selective eosinophil adhesion to fibroblast via IFN-gamma-induced
galectin-9. J Immunol. 169:5912–5918. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dai SY, Nakagawa R, Itoh A, Murakami H,
Kashio Y, Abe H, Katoh S, Kontani K, Kihara M, Zhang SL, et al:
Galectin-9 induces maturation of human monocyte-derived dendritic
cells. J Immunol. 175:2974–2981. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nobumoto A, Oomizu S, Arikawa T, Katoh S,
Nagahara K, Miyake M, Nishi N, Takeshita K, Niki T, Yamauchi A, et
al: Galectin-9 expands unique macrophages exhibiting plasma-cytoid
dendritic cell-like phenotypes that activate NK cells in
tumor-bearing mice. Clin Immunol. 130:322–330. 2009. View Article : Google Scholar
|
|
13
|
Wiersma VR, de Bruyn M, Helfrich W and
Bremer E: Therapeutic potential of Galectin-9 in human disease. Med
Res Rev. 33(Suppl 1): E102–E126. 2013. View Article : Google Scholar
|
|
14
|
Fujihara S, Mori H, Kobara H, Rafiq K,
Niki T, Hirashima M and Masaki T: Galectin-9 in cancer therapy.
Recent Pat Endocr Metab Immune Drug Discov. 7:130–137. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kashio Y, Nakamura K, Abedin MJ, Seki M,
Nishi N, Yoshida N, Nakamura T and Hirashima M: Galectin-9 induces
apoptosis through the calcium-calpain-caspase-1 pathway. J Immunol.
170:3631–3636. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu LH, Nakagawa R, Kashio Y, Ito A, Shoji
H, Nishi N, Hirashima M, Yamauchi A and Nakamura T:
Characterization of galectin-9-induced death of Jurkat T cells. J
Biochem. 141:157–172. 2007. View Article : Google Scholar
|
|
17
|
Kobayashi T, Kuroda J, Ashihara E, Oomizu
S, Terui Y, Taniyama A, Adachi S, Takagi T, Yamamoto M, Sasaki N,
et al: Galectin-9 exhibits anti-myeloma activity through JNK and
p38 MAP kinase pathways. Leukemia. 24:843–850. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kuroda J, Yamamoto M, Nagoshi H, Kobayashi
T, Sasaki N, Shimura Y, Horiike S, Kimura S, Yamauchi A, Hirashima
M, et al: Targeting activating transcription factor 3 by Galectin-9
induces apoptosis and overcomes various types of treatment
resistance in chronic myelogenous leukemia. Mol Cancer Res.
8:994–1001. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nishi N, Itoh A, Fujiyama A, Yoshida N,
Araya S, Hirashima M, Shoji H and Nakamura T: Development of highly
stable galectins: Truncation of the linker peptide confers
protease-resistance on tandem-repeat type galectins. FEBS Lett.
579:2058–2064. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schutte B, Henfling M, Kölgen W, Bouman M,
Meex S, Leers MP, Nap M, Björklund V, Björklund P, Björklund B, et
al: Keratin 8/18 breakdown and reorganization during apoptosis. Exp
Cell Res. 297:11–26. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Laemmli UK: Cleavage of structural
proteins during the assembly of the head of bacteriophage T4.
Nature. 227:680–685. 1970. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Towbin H, Staehelin T and Gordon J:
Electrophoretic transfer of proteins from polyacrylamide gels to
nitrocellulose sheets: Procedure and some applications. Proc Natl
Acad Sci USA. 76:4350–4354. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
D'Incalci M, Colombo T, Ubezio P,
Nicoletti I, Giavazzi R, Erba E, Ferrarese L, Meco D, Riccardi R,
Sessa C, et al: The combination of yondelis and cisplatin is
synergistic against human tumor xenografts. Eur J Cancer.
39:1920–1926. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kageshita T, Kashio Y, Yamauchi A, Seki M,
Abedin MJ, Nishi N, Shoji H, Nakamura T, Ono T and Hirashima M:
Possible role of galectin-9 in cell aggregation and apoptosis of
human melanoma cell lines and its clinical significance. Int J
Cancer. 99:809–816. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Irie A, Yamauchi A, Kontani K, Kihara M,
Liu D, Shirato Y, Seki M, Nishi N, Nakamura T, Yokomise H, et al:
Galectin-9 as a prognostic factor with antimetastatic potential in
breast cancer. Clin Cancer Res. 11:2962–2968. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nagahara K, Arikawa T, Oomizu S, Kontani
K, Nobumoto A, Tateno H, Watanabe K, Niki T, Katoh S, Miyake M, et
al: Galectin-9 increases Tim-3+ dendritic cells and
CD8+ T cells and enhances antitumor immunity via
galectin-9-Tim-3 interactions. J Immunol. 181:7660–7669. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kramer G, Erdal H, Mertens HJ, Nap M,
Mauermann J, Steiner G, Marberger M, Bivén K, Shoshan MC and Linder
S: Differentiation between cell death modes using measurements of
different soluble forms of extracellular cytokeratin 18. Cancer
Res. 64:1751–1756. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Linder S: Cytokeratin markers come of age.
Tumour Biol. 28:189–195. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cummings J, Ranson M, Butt F, Moore D and
Dive C: Qualification of M30 and M65 ELISAs as surrogate biomarkers
of cell death: Long term antigen stability in cancer patient
plasma. Cancer Chemother Pharmacol. 60:921–924. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Scott LC, Evans TR, Cassidy J, Harden S,
Paul J, Ullah R, O'Brien V and Brown R: Cytokeratin 18 in plasma of
patients with gastrointestinal adenocarcinoma as a biomarker of
tumour response. Br J Cancer. 101:410–417. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Varnholt H: The role of microRNAs in
primary liver cancer. Ann Hepatol. 7:104–113. 2008.PubMed/NCBI
|
|
32
|
Tan S, Li R, Ding K, Lobie PE and Zhu T:
miR-198 inhibits migration and invasion of hepatocellular carcinoma
cells by targeting the HGF/c-MET pathway. FEBS Lett. 585:2229–2234.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang J, Zhao H, Xin Y and Fan L:
MicroRNA-198 inhibits proliferation and induces apoptosis of lung
cancer cells via targeting FGFR1. J Cell Biochem. 115:987–995.
2014. View Article : Google Scholar
|
|
34
|
Marin-Muller C, Li D, Bharadwaj U, Li M,
Chen C, Hodges SE, Fisher WE, Mo Q, Hung MC and Yao Q: A
tumorigenic factor interactome connected through tumor suppressor
microRNA-198 in human pancreatic cancer. Clin Cancer Res.
19:5901–5913. 2013. View Article : Google Scholar : PubMed/NCBI
|
